Last updated on June 2018

CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia AML


Brief description of study

The purpose of this study is to evaluate the safety and efficiency of CD123-Targeted CAR-T in Treating Patients with relapsed/refractory AML

Detailed Study Description

The relapsed/refractory AML patients will receive FC (F,FludarabineCCyclophosphamide) chemotherapy followed by infusion of allogenic or autologous CD123-Targeted CAR-T cells.No graft-versus-host disease (GVHD) prevention will be conducted before or after infusion. Dose-limiting toxicity,incidence of adverse events and disease response will be detected post-infusion.

Clinical Study Identifier: NCT03556982

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.